Loading company financials…
NEW YORK STOCK EXCHANGE, INC. · Health Care · CIK 0000064803
$94.48
+1.10% · live
Updated
$120.08B market value
From CVS HEALTH Corp's FY2025 10-K, filed Feb 10, 2026 · read the filing
CVS HEALTH runs retail stores. It took in $402.07B last year, which makes it one of the largest companies in the world. Of every dollar it sells, about 0 cents is left as profit.
The financial picture is mixed, with profitability and growth needing attention and debt weaker.
A conclusion from the filings, not a recommendation. Detailed figures and supporting evidence appear in their dedicated sections below.
A published bankruptcy-risk model places it in its distress range. This is a statistical reading, not a forecast.
Altman Z-Score 0.99
These are things the company filed or that a published model flagged — not predictions, and not a reason on their own to buy or sell anything.
Financial health
A mixed picture — some clear strengths and some weaknesses.
From CVS HEALTH Corp's FY2025 annual filing · share price scored separately
Largest year-over-year changes in FY2025
Operating income
$8.52B → $4.66B
Profit
$4.61B → $1.77B
Earnings per share
$3.66 → $1.39
Free cash flow
$6.33B → $7.81B
Measured against FY2024, from the 10-K filed Feb 10, 2026
Deteriorated: -45.3%
$8.52B to $4.66BCritical
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Deteriorated: -61.7%
$4.61B to $1.77BCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
How the latest move compares (quote live), and what was published around it
CVS rose 1.10% on the latest quote. The average Consumer Discretionary company tracked here moved +2.33%, and the S&P 500 −1.04%. That is 1.2 points below its sector and 2.1 points above the market.
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
Opinions from 32 analysts covering this company, as of . Their views, not this site's.
Of 32 analysts publishing on this company, 8 say strong buy, 20 say buy and 4 say hold. Analysts are paid to publish a view and are wrong often; the split above says how much they agree with each other, which is the part a single headline rating hides.
Published by Finnhub. Analyst coverage skews towards larger companies and towards optimism — sell ratings are rare across the whole market, so a company with none is ordinary rather than endorsed.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 0 cents of every dollar of sales as profit, earning $1.77B last year.
Slowly. Sales grew 7.8% last year.
Manageable, but notable. Clearing its debt would take about 4.9 years of cash flow. For every $1 it owes, it owns $1.42 in assets. A bankruptcy-risk model also places it in its distress range.
Core operating and valuation reference metrics
Whether the dividend is covered by what the business actually earns
It paid out more than it earned — 192 cents for every dollar of profit. A payment above earnings has to be funded from somewhere else, so it is worth checking whether that can continue. It paid out 32% of the cash its operations generated. It has paid in each of the last 12 years.
WeakNext payment expected around , projected from how regularly it has paid before rather than from a date the company has announced.
Figures from the FY2025 annual filing
Last year it earned $1.77B and generated $10.64B of cash from operations.
Reported annual figures
As reported to the SEC, in USD. Hover or show sources to see where each figure came from.
| Income statement | FY202510-K · Feb 10, 2026Filing for FY2025 | FY202410-K · Feb 12, 2025Filing for FY2024 | FY202310-K · Feb 7, 2024Filing for FY2023 | FY202210-K · Feb 7, 2024Filing for FY2022 | FY202110-K · Feb 7, 2024Filing for FY2021 | ChangeFY2025 vs FY2024 |
|---|---|---|---|---|---|---|
| RevenueWhat is this? | $402.07B | $372.81B | $357.78B | $322.47B | $292.11B | +7.8% |
| Cost of revenue | $221.17B | $206.29B | $217.10B | $196.89B | $175.80B | +7.2% |
| Gross profit | $180.90B† | $166.52B† | $140.68B† | $125.58B† | $116.31B† | +8.6% |
| Gross marginGross profit ÷ revenueWhat is this? | 45.0% | 44.7% | 39.3% | 38.9% | 39.8% | +0.3 pts |
| Operating income | $4.66B | $8.52B | $13.74B | $7.95B | $13.31B | −45.3% |
| Operating marginOperating income ÷ revenueWhat is this? | 1.2% | 2.3% | 3.8% | 2.5% | 4.6% | −1.1 pts |
| Interest expense | $3.12B | $2.96B | $2.66B | $2.29B | $2.50B | +5.4% |
| Income before tax | $2.14B | $6.15B | $11.17B | $5.84B | $10.54B | −65.3% |
| Net income | $1.77B | $4.61B | $8.34B | $4.31B | $8.00B | −61.7% |
| Net marginNet income ÷ revenueWhat is this? | 0.4% | 1.2% | 2.3% | 1.3% | 2.7% | −0.8 pts |
| Earnings per shareNet income ÷ shares outstanding at the period end — close to, but not the same as, the reported EPSWhat is this? | $1.39 | $3.66 | $6.48 | $3.32 | $6.05 | −62.0% |
† calculated from other reported figures, such as total liabilities as assets minus equity.
This company's latest filing beside its peers' stored scores
| Company | Health | F-Score | Revenue growth | Profit margin | P/E | Debt to equity |
|---|---|---|---|---|---|---|
| CVSCVS HEALTH Corp · this page | 4.7/10 | 8/9 |
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Officers, directors and major shareholders must report within two business days of a trade.
Had shares withheld to cover taxes — 454 shares at $90.98 ($41.3K)
Holds 27,606 shares after this filing.
Estimated from how often this has happened before, not a confirmed date.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
20 recent filings, newest first. Each is labelled from its form and item numbers, not from its wording.
Had a director or senior officer leave or join · Made a Regulation FD disclosure
Read the filingQuarterly report for Q2 FY2026
Revenue +7.3% · Operating margin +2.0 pts · Operating income +97.5% — against Q2 FY2025
Read the filingWrite down why you are following CVS HEALTH Corp, what has to go right and what would change your mind, then see each new annual report measured against it. Sign in to start one.
Go deeper
Every figure above traces back to a filing in the timeline, each linked to the document itself.
Coverage from the last 30 days
A 14.9% Dividend Yield Sounds Great. Western Union Shows Why It Could Be a Trap
Yahoo ·
CVS Health: Thank You! 101 Factory Farmer's Market & Cul2vate Employee Appreciation Day in Nashville, Tennessee
Yahoo ·
Which women leaders do top execs admire?
Yahoo ·
What Does Progyny's Falling Multiple Really Say?
Yahoo ·
CVS Health (CVS) Stock Sinks As Market Gains: What You Should Know
Yahoo ·
Every company's figures are checked for internal consistency: the balance sheet adding up, figures sharing one currency, cash flow and share counts within plausible ranges, and how recent the latest annual report is. Nothing here changes a figure.
Financial figures are from CVS's 10-K for fiscal year 2025 (period ending 2025-12-31, filed Feb 10, 2026), reported under the US GAAP taxonomy. View the source filing.
3 of 4 scored areas had enough reported figures to judge
The score averages profitability, growth, debt and accounting. Accounting had too few reported figures and is left out of the average rather than counted as a weakness, so a company is never marked down for a figure it did not publish. Cash generation is shown for context and already feeds profitability. Valuation is scored separately, because a share price says nothing about whether the business is sound. 9 of the 9 Piotroski checks could be evaluated. How the score works
Each year scored only from its annual report as it was first filed
| Fiscal year | Health | F-Score | Scored from |
|---|---|---|---|
| FY2025 | 4.7 | 8/9 | 10-K, filed Feb 10, 2026 |
| FY2024 | 4.7 | 6/9 | 10-K, filed Feb 12, 2025 |
| FY2023 | 6.0 | 7/9 | 10-K, filed Feb 7, 2024 |
| FY2022 | 7.3 | 7/9 | 10-K, filed Feb 8, 2023 |
| FY2021 | 7.3 | 8/9 | 10-K, filed Feb 9, 2022 |
| FY2020 | 6.0 | 8/9 | 10-K, filed Feb 16, 2021 |
A later restatement never reaches back into an earlier year, and every year is scored without a share price, so the latest point can differ a little from the headline score, which uses today's price.
Every check behind the three models, and what each one tests
8 of 9 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's.
0.99
In the distress zone
For this model, above 2.6 is safe and below 1.1 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
not reported — This company has not reported enough of the required figures to calculate this score.
This company has not reported enough of the required figures to calculate this score.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Deteriorated: -62.0%
$3.66 to $1.39Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +23.4%
$6.33B to $7.81BSignificant
Why it matters: Cash left after paying for the plant that produced it — the money genuinely available for dividends, buybacks or paying down debt. Harder to flatter than profit.
Improved: +7.8%
$372.81B to $402.07BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +8.6%
$166.52B to $180.90BNotable
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Deteriorated: −1.1 pts
2.3% to 1.2%Notable
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Q2 FY2026 against Q2 FY2025, from the 10-Q filed Aug 5, 2026 — read it.
Improved: +97.5%
$2.38B to $4.70BCritical
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: +191.8%
$1.02B to $2.98BCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +189.3%
$0.81 to $2.33Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +7.3%
$98.92B to $106.10BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +5.2%
$44.91B to $47.23BNotable
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Improved: +2.0 pts
2.4% to 4.4%Notable
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Improved: +1.8 pts
1.0% to 2.8%Notable
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Q2 FY2026 against Q1 FY2026, from the 10-Q filed Aug 5, 2026 — read it. Quarter-to-quarter moves include seasonal swings — a retailer's holiday quarter — which the year-earlier comparison removes.
Improved: +18.7%
$9.54B to $11.33BSignificant
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: +5.6%
$100.43B to $106.10BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +5.0%
$44.98B to $47.23BNotable
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
7 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Moves are graded on fixed lines — 5%, 15% and 40% for amounts, and 1, 3 and 8 points for margins — as notable, significant or critical. Nothing here reads the management commentary, which is where a company explains its own numbers.
These coincide with the move in time. None is presented as its cause: a price can move on news that names no company, on the wider market, or on trading that no document records.
Filter by minute, hour, day or week — or compare against peers
Loading price history…
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 1.3% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
The trailing P/E is 40.5x — a high multiple relative to the current trailing profit.
This company has not reported enough of the required figures to calculate this score.
| 7.8% |
| 0.4% |
| 67.92x |
| 2.37x |
| CICigna Group | 6.0/10 | 7/9 | 11.2% | 2.2% | 13.97x | 2.78x |
|---|
| DGXQUEST DIAGNOSTICS INC | 8.0/10 | 8/9 | 11.8% | 9.0% | 27.22x | 1.26x |
|---|
| LHLABCORP HOLDINGS INC. | 7.0/10 | 8/9 | 7.2% | 6.3% | 30.94x | 1.13x |
|---|
| DVADAVITA INC. | 4.7/10 | 6/8 | 6.5% | 5.5% | 17.08x | -25.07x |
|---|
| Median of peers | 6.5/10 | — | 9.2% | 5.9% | 22.15x | 1.20x |
|---|
Peers come from the company's industry classification. A difference describes the companies; it does not rank them.
Published results
Had a director or senior officer leave or join · Held a shareholder vote
Read the filingQuarterly report for Q1 FY2026
Revenue +6.2% · Operating margin +1.1 pts · Profit +65.4% — against Q1 FY2025
Read the filingPublished results
Read the filingProxy statement for a shareholder meeting
Read the filingHad a director or senior officer leave or join
Read the filingAnnual report for FY2025
Revenue +7.8% · Operating margin −1.1 pts · Operating income -45.3% — against FY2024
Read the filingPublished results
Read the filingMade a Regulation FD disclosure
Read the filingReported another event
Read the filingQuarterly report for Q3 FY2025
Revenue +7.8% · Operating margin −4.0 pts · Operating income turned negative — against Q3 FY2024
Read the filingPublished results
Read the filingReported another event
Read the filingReported another event
Read the filingQuarterly report for Q2 FY2025
Revenue +8.4% · Profit -42.3% · Earnings per share -42.8% — against Q2 FY2024
Read the filingPublished results
Read the filingHeld a shareholder vote
Read the filingQuarterly report for Q1 FY2025
Revenue +7.0% · Operating margin +1.0 pts · Operating income +48.6% — against Q1 FY2024
Read the filingPrimary sources and further research